Skip to content

On this page

Ebanga

ansuvimab-zykl

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Ebanga

Proper name

ansuvimab-zykl

Licence type

351(a)

BLA number

761172

Applicant

Emergent BioDefense Operations Lansing LLC

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
400MG	For Injection	Intravenous	Single-Dose Vial	Rx	December 21, 2020

Exclusivity

Source: Purple Book

Kind	Expires
Orphan exclusivity	December 21, 2027

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity